Healthcare >> Analyst Interviews >> April 20, 1998
ELIZABETH SILVERMAN, a vice president, joined BancAmerica Robertson
Stephens (BARS) in 1997 as a senior research analyst focusing on
genomics and new technologies related to drug discovery. Previously, she
was a biotech analyst at Punk, Ziegel & Company. She has more than ten
years of experience in the pharmaceutical and biotechnology industries
and has worked in international health care consulting. She holds a BA
from the University of Chicago, an MS from Columbia University and a MBA
from New York University. Profile
have impacted the genomics companies, both in terms of scientific
development and business developments?
Ms. Silverman:
